ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Market Cap	$3.46B	P/E Ratio	31.61
52W High	$25.67	52W Low	$13.50
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	54.2%	52W Position	55.3%
Overall Score	65	Value Score	60
Quality Score	71	Technical Score	66

EPS Current Est	$0.64	EPS Next Est	$0.9
EPS Growth Est	+40.6%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ADMA	$20.23	+1.25%	929.08K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ADMA	$20.23	+1.3%	929.08K
3
4
5
6

ADMA

ADMA

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get ADMA Biologics Inc Data in Excel

Get ADMA Biologics Inc Data in Excel